Sign up to save your podcasts
Or
Share Scaling CAR-T for Autoimmune Disease: Warner Biddle on Kyverna’s Breakthrough Strategy
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Scaling CAR-T for Autoimmune Disease: Warner Biddle on Kyverna’s Breakthrough Strategy
In this episode of the IDEA Collider, host Mike Rea sits down with Warner Biddle, CEO of Kyverna Therapeutics, to explore how CAR-T cell therapy is expanding beyond oncology into autoimmune disease—and what it takes to scale one of the most complex innovations in modern medicine.
Warner shares insights from his career across large pharma and biotech, breaking down why cell therapy requires a fundamentally different operating model—one that tightly integrates manufacturing, clinical execution, and commercialization. The conversation dives into how Kyverna is advancing CAR-T therapies for neuroimmunology indications, including stiff person syndrome (SPS), myasthenia gravis, multiple sclerosis, and rheumatoid arthritis, while preparing its first Biologics License Application (BLA).
They also unpack the broader cell therapy ecosystem, from improving hospital capacity and enabling outpatient treatment to evolving FDA regulatory pathways, CMC guidance, and REMS simplification—all critical to making CAR-T more accessible and scalable. Warner emphasizes that success in this space depends on trust-driven leadership, speed, and a willingness to embrace risk, while also highlighting the growing global competition—particularly from China—as a catalyst for faster innovation.
Episode Timestamps
00:00 – Introduction to CAR-T and the future of autoimmune disease treatment
00:18 – Meet Warner Biddle and his journey across pharma and biotech
01:26 – Building a culture of innovation, trust, and speed
02:45 – Why cell therapy is fundamentally different from traditional drugs
03:57 – Ecosystem shifts: access, infrastructure, and outpatient care
06:03 – FDA tailwinds: CMC guidance, REMS changes, and regulatory momentum
07:24 – Kyverna’s strategy and rapid progress in stiff person syndrome (SPS)
09:04 – Manufacturing challenges and scaling CAR-T production
10:25 – Commercializing one-time therapies in a traditional pharma model
11:47 – Clinical impact of CAR-T in autoimmune diseases
13:32 – Investor momentum and biotech market dynamics
14:13 – Leadership principles: trust, urgency, and decision-making
18:33 – Scaling biotech while maintaining agility
20:56 – Expanding access: bringing CAR-T to community settings
23:24 – China’s accelerating innovation in cell therapy
26:18 – 2026 milestones and Kyverna’s pipeline outlook
29:43 – Closing thoughts
Don't forget to Like, Share, Subscribe, Rate, and Review!
Keep up with Warner Biddle;
LinkedIn: https://www.linkedin.com/in/warnerbiddle/
Website: https://kyvernatx.com/
Follow IDEA Pharma On;
Website: https://www.ideapharma.com/ & https://www.sai-med.com/
LinkedIn: https://www.linkedin.com/company/idea-pharma
Listen to more fantastic podcast episodes: https://ideacollider.simplecast.com/
View all episodes
By IDEA Pharma, SAI MedPartners
5
22 ratings
In this episode of the IDEA Collider, host Mike Rea sits down with Warner Biddle, CEO of Kyverna Therapeutics, to explore how CAR-T cell therapy is expanding beyond oncology into autoimmune disease—and what it takes to scale one of the most complex innovations in modern medicine.
Warner shares insights from his career across large pharma and biotech, breaking down why cell therapy requires a fundamentally different operating model—one that tightly integrates manufacturing, clinical execution, and commercialization. The conversation dives into how Kyverna is advancing CAR-T therapies for neuroimmunology indications, including stiff person syndrome (SPS), myasthenia gravis, multiple sclerosis, and rheumatoid arthritis, while preparing its first Biologics License Application (BLA).
They also unpack the broader cell therapy ecosystem, from improving hospital capacity and enabling outpatient treatment to evolving FDA regulatory pathways, CMC guidance, and REMS simplification—all critical to making CAR-T more accessible and scalable. Warner emphasizes that success in this space depends on trust-driven leadership, speed, and a willingness to embrace risk, while also highlighting the growing global competition—particularly from China—as a catalyst for faster innovation.
Episode Timestamps
00:00 – Introduction to CAR-T and the future of autoimmune disease treatment
00:18 – Meet Warner Biddle and his journey across pharma and biotech
01:26 – Building a culture of innovation, trust, and speed
02:45 – Why cell therapy is fundamentally different from traditional drugs
03:57 – Ecosystem shifts: access, infrastructure, and outpatient care
06:03 – FDA tailwinds: CMC guidance, REMS changes, and regulatory momentum
07:24 – Kyverna’s strategy and rapid progress in stiff person syndrome (SPS)
09:04 – Manufacturing challenges and scaling CAR-T production
10:25 – Commercializing one-time therapies in a traditional pharma model
11:47 – Clinical impact of CAR-T in autoimmune diseases
13:32 – Investor momentum and biotech market dynamics
14:13 – Leadership principles: trust, urgency, and decision-making
18:33 – Scaling biotech while maintaining agility
20:56 – Expanding access: bringing CAR-T to community settings
23:24 – China’s accelerating innovation in cell therapy
26:18 – 2026 milestones and Kyverna’s pipeline outlook
29:43 – Closing thoughts
Don't forget to Like, Share, Subscribe, Rate, and Review!
Keep up with Warner Biddle;
LinkedIn: https://www.linkedin.com/in/warnerbiddle/
Website: https://kyvernatx.com/
Follow IDEA Pharma On;
Website: https://www.ideapharma.com/ & https://www.sai-med.com/
LinkedIn: https://www.linkedin.com/company/idea-pharma
Listen to more fantastic podcast episodes: https://ideacollider.simplecast.com/